ATOVAQUONE Drug Patent Profile
✉ Email this page to a colleague
When do Atovaquone patents expire, and what generic alternatives are available?
Atovaquone is a drug marketed by Abhai Llc, Abon Pharms Llc, Amneal Pharms, Apotex, Bionpharma, Chartwell Rx, Glenmark Speclt, Hetero Labs Ltd Iii, Lupin Ltd, Glenmark Pharms Ltd, and Mylan. and is included in eleven NDAs.
The generic ingredient in ATOVAQUONE is atovaquone; proguanil hydrochloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the atovaquone; proguanil hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Atovaquone
A generic version of ATOVAQUONE was approved as atovaquone; proguanil hydrochloride by GLENMARK PHARMS LTD on January 12th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ATOVAQUONE?
- What are the global sales for ATOVAQUONE?
- What is Average Wholesale Price for ATOVAQUONE?
Summary for ATOVAQUONE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 18 |
| Raw Ingredient (Bulk) Api Vendors: | 166 |
| Clinical Trials: | 42 |
| Patent Applications: | 5,763 |
| Drug Prices: | Drug price information for ATOVAQUONE |
| DailyMed Link: | ATOVAQUONE at DailyMed |
Recent Clinical Trials for ATOVAQUONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Naval Medical Research Center | Phase 4 |
| Naval Environmental Preventive Medicine Unit TWO (NEPMU-2) | Phase 4 |
| The 108 Military Central Hospital | Phase 4 |
Pharmacology for ATOVAQUONE
| Drug Class | Antimalarial Antiprotozoal |
Medical Subject Heading (MeSH) Categories for ATOVAQUONE
Anatomical Therapeutic Chemical (ATC) Classes for ATOVAQUONE
Paragraph IV (Patent) Challenges for ATOVAQUONE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MEPRON | Oral Suspension | atovaquone | 750 mg/5 mL | 020500 | 1 | 2009-10-20 |
US Patents and Regulatory Information for ATOVAQUONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abhai Llc | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 210510-001 | May 31, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glenmark Speclt | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 209685-001 | Nov 21, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | ATOVAQUONE | atovaquone | SUSPENSION;ORAL | 209750-001 | Oct 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
